“FDA will take swift action against companies mass-marketing illegal copycat drugs, claiming they are similar to FDA-approved products,” FDA commissioner Marty Makary, M.D., said in a Feb. 5 post on X. The comments mark a clear and sharp rebuttal to
read moreOn Thursday evening, President Donald Trump is set to debut TrumpRx, a government-run website that will direct patients toward cash-pay channels where they can purchase certain prescription drugs. More: TrumpRx, US government's cash-pay drug purchasing portal, primed for launch Source:
read moreA month after drugmaker Novo Nordisk launched its Wegovy pill, online health and wellness company Hims & Hers plans to undercut it with a compounded semaglutide pill offered at a lower price. More: Him & Hers plans to offer cheaper
read moreThe majority of Bristol Myers Squibb’s $48.2 billion revenue haul in 2025 came from its collection of newer growth products as its legacy portfolio declines. More: With declining sales of legacy meds, BMS leans on new growth drivers to weather
read moreAstellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales. More: Astellas tops expectations as Vyloy sales surge outshines trial setback Source: fierce
read moreIn its initial public offering, Veradermics sold a little over 15 million shares of common stock at $17 apiece, raising a total of $256.3 million in its entry onto the New York Stock Exchange, according to a Securities and Exchange
read more© 1994 - 2026 B.M. Pharmaceuticals